

Magle Chemoswed's offer oversubscribed - trading is scheduled to begin on Nasdaq First North Growth Market on June 30

Magle Chemoswed Holding AB ("Magle Chemoswed" or the "Company") has completed the offer to the public in Sweden and institutional investors to acquire existing shares in the Company (the "Offer"). The offer amounted to SEK 50 million and was subscribed to approximately SEK 106 million. First day of trading on Nasdaq First North Growth Market ("Nasdaq First North") is scheduled for June 30, 2020.

The offer in brief

- The price per share in the Offer was SEK 20, corresponding to a value of SEK 200 million for the total number of shares in Magle Chemoswed.
- The offer consisted of 2,500,000 existing shares in the Company, corresponding to SEK 50 million.
- The selling shareholder is Magle AB, a company that indirectly is wholly owned by Hans Henrik Lidgard who also owns all shares in the Company prior to the Offer. After the Offer, Magle AB will own approximately 74 percent of the shares and votes in the Company.[1]
- Prior to the Offer, Fosielund Holding AB, Tibia Konsult AB and Birka Stock AB had undertaken, at the same price as for other investors, to acquire shares in the Offer at a value of SEK 28 million. In addition, board members and a limited number of investors had undertaken to acquire shares corresponding to a total of SEK 10.75 million at the same price and under the same conditions as other investors in the Offer. In total, the Offer was thus covered by commitments amounting to SEK 38.75 million.
- Through the Offer, Magle Chemoswed has added just over 1 500 new shareholders.
- Trading in Magle Chemoswed is expected to begin on Nasdaq First North June 30, 2020.
- The shares will be traded under the short name "MAGLE" with ISIN code SE0014401014.
- The settlement date for the Offer is June 26, 2020.

CEO, Justin Pierce, comments

"We are very pleased with the great interest in the Magle Chemoswed share and the Offer. We welcome all new shareholders. The listing on Nasdaq First North Growth Market provides us with a good basis for continuing to generate growth and returns for our shareholders in the future."

Advisors and issuing agent

Västra Hamnen Corporate Finance is the financial advisor to Magle Chemoswed in connection with the Offer. Advokatfirman Vinge is legal counsel. Aqurat Fondkommission acts as issuing agent. Nordnet acts as selling agent in the Offer.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

For more information, please contact

Justin Pierce, CEO, Magle Chemoswed Holding AB

Tel: +46 46 (0)70 59 358 21

Email: Justin.Pierce@maglechemoswed.com

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions in which this press release has been released, announced or distributed shall inform themselves of and follow such restrictions.

This press release does not constitute an offer, or a solicitation of any offer, to purchase or subscribe for or otherwise trade with any securities in Magle Chemoswed in any jurisdiction and investors shall not subscribe or acquire any securities other than on the basis of the information in the published prospectus.

Magle Chemoswed has not taken and will not take any measures to allow a public offering in any other jurisdiction than Sweden. The Offer is not directed, directly or indirectly, to persons whose participation requires additional prospectus, registration or other measures than those required under Swedish law. The prospectus, the application form or other documents relating to the Offer may not be distributed in or to a country where distribution or the Offer would require any such measures to be taken, or that otherwise would violate applicable laws or regulations in such country.

The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into, to the United States, Australia, Canada, Japan or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations, or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Acquisitions of shares in violation of the abovementioned restrictions may be invalid.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Magle Chemoswed has not registered or intends to register any issued shares or securities under the Securities Act, nor under any corresponding law in any state in the United States, or applicable law in any country other than Sweden. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of the (EU) Regulation 2017/1129 (the Prospectus Regulation) and has not been approved by any national competent authority in any jurisdiction.

This press release contains certain forward-looking statements on market information that reflect the Company's current view of future events as well as financial and operational development. Words such as "intended", "assessed", "expected", "can", "planned", "estimated" and other

expressions that imply indications or predictions regarding future developments or trends and which are not based on historical facts constitute forward-looking statements. Forward-looking statements is inherently associated with both known and unknown risks and uncertainties, as it is dependent on future events and circumstances. Forward-looking statements do not constitute a guarantee for future results or development, and actual results may differ materially from what is stated in forward-looking statements. This information, the opinions and the forward-looking statements contained in this press release are valid only at this date and are subject to change without notice thereof

[1] In connection with the Offer, Magle AB has transferred 103 600 shares, corresponding to approximately 1 percent of the number of shares and votes in the Company, to certain Hans Henrik Lidgard related parties.

About Us

We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on www.maglechemoswed.com.

Attachments

[Magle Chemoswed's offer oversubscribed - trading is scheduled to begin on Nasdaq First North Growth Market on June 30](#)